What is the clinical application of Ocriplasmin in my country?

Ocriplasmin (Ocriplasmin) is a genetically recombinant protease, a new drug in the field of ophthalmology, and is mainly used in the treatment of vitreomacular interface diseases. By being directly injected into the vitreous cavity, the drug can cut off the adhesion between the vitreous body and the macula, thereby achieving drug-induced vitreous separation. This mechanism provides a new non-surgical solution for diseases that could only be solved through vitrectomy surgery in the past, and also represents an important progress in precision ophthalmology treatment. In international clinical practice, Oakplasmin has been used to treat vitreomacular traction (VMT), macular holes and other indications associated with epiretinal membrane, and has achieved certain results.

In my country, the clinical application of Oak plasmin is still in the stage of gradual promotion, and it has not yet been used on a large scale like in European and American countries. Domestic ophthalmologists still focus on surgery when treating macular holes andVMT. However, as patients become more accepting of minimally invasive, incision-free treatments, Oakplasmin is expected to play a greater role in clinical practice in the future. Especially in some cases where surgical risks are high or patients are unwilling to undergo vitrectomy, drug injection can become a new treatment path.

In addition, domestic academic research on Oak plasmin mainly focuses on efficacy evaluation and safety observation. Some retrospective analyzes show that the drug has positive significance in improving patients' visual function and promoting posterior vitreous detachment. But at the same time, some doctors are concerned that its indications need to be strictly screened. Only specific types of VMT or macular holes are suitable for use, otherwise the efficacy of the drug may be limited. As domestic guidelines and clinical pathways gradually improve, Oakplasmin is expected to enter the routine treatment of ophthalmology in more tertiary hospitals.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html